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Edited by Lukas HuberAbstract Alternative cell signal transduction pathways have
been demonstrated in some experimental systems. The impor-
tance of their existence has not been completely appreciated.
In this review we present the cases of alternative pathways
resulted from a survey of the available experimental data. The
alternative pathways could show diﬀerent relationships, i.e.,
synergistic, redundant, additive, opposite and competitive eﬀects.
They could have distinct time courses and cell, organ, sex or
species speciﬁcation. Further, they could happen during physio-
logical or pathological situations, and display diﬀerentiated
sensitivity. These case studies together imply that alternative
signal pathways could be involved in the regulation of cell
functions at the pathway level. In-depth understanding of the
importance of the alternative pathways will rely on building
and exploration of mathematical models.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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According to the book, Signal Transduction [1], the term
signal transduction ﬁrst appeared in the biological literature in
around 1974. Now it is a key word for more than 120000 Pub-
Med abstracts, including over 30000 review articles. It has been
developed to a unique research area of biology and medicine in
general. Studies and results on signaling pathways span from
molecular level, which includes structure and interaction of
the signaling molecules, to their phenotypic and pathological
eﬀects. The importance of the study in this area resides in that
almost all cellular functions and phenotypes are results of spe-
ciﬁc signal transduction. From the therapeutic point of view,
we are expecting to inhibit or activate a speciﬁc signaling path-
way to achieve the cure of a disease. Unfortunately, the cell
signaling pathways are usually woven together. They could
diverge, in that, one stimulus activates multi-pathways to
multi-targets, which could induce diﬀerent cell functions, some
of them could be inverse. They could also converge, in that,
signaling from diﬀerent sources of stimuli would activate the
same downstream target, and induce the same cell function.
Thus, the combination of the signaling pathways from diver-
gent stimuli will form a network. This makes it almost impos-*Corresponding author.
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To make thing even worse, it can be usually found that
multi-pathways exist from one stimulus to a single target. As
early as in 1954, the term alternative pathway had appeared
for glucose metabolism [2]. It is now used to represent any of
above situations. We assume that the alternative pathways
occur at diﬀerent time points and diﬀerent cells or organs,
and be important for the network robustness and the spatial
and temporal regulation of the cell functions. To support this
notion, in this article we present a review of the case studies
relating to alternative signaling pathways under a variety of
circumstances, focusing on the situations and possible biologi-
cal importance for the alternative pathways to exist.
Fig. 1 shows schematic diagrams of ﬁve types of alternative
pathways with real biological examples. Roughly, we use ele-
ment types A (divergent), V (convergent) and O (single/multi-
ple), and complex types M (multiple/multiple) and N (nested)
to depict diﬀerent kinds of the alternative pathways and their
combinations. This nomenclature is quite straightforward,
with A representing one stimulus to multiple targets, V repre-
senting multiple stimuli to one target, O representing one
stimulus to one target via multiple pathways. While type M
is the combination of types A and V, representing multiple
stimuli to multiple targets with cross-talks between the multi-
ple pathways, and the type N can be seen as the combination
of all other types. The element types are local, and the trend is
that global networks will be always composed of complex
types of alternative pathways.2. Relationship between the alternative pathways
2.1. Synergistic/complementary eﬀects of alternative pathways
If the alternative pathways have synergistic eﬀects, they are
all needed for the proper cell functions. This is equivalent to
an AND gate in electronic circuits [3] (Fig. 2). Biochemical
mechanism for the synergistic eﬀects could be the necessity
of a pre-modiﬁcation for a ﬁnal modiﬁcation of the signaling
target. This scenario is exempliﬁed by the activation of CFTR
(cystic ﬁbrosis transmembrane conductance regulator) during
ICl,ATP (ATP dependent Cl
 current) production, where extra-
cellular ATPcS (adenosine-5 0-O-(3-thiotriphosphate)) elicits
the purinergic receptors signaling, results in two pathways to
CFTR via PKC (protein kinase C) and PKA (protein kinase
A), respectively. Phosphorylation of CFTR by PKA occurs
only after its phosphorylation by PKC [4,5]. Stimulation of
cAMP (cyclic-AMP), a signal mediator upstream of PKA, by
isoprenaline or FK (forskolin), will not activate CFTR [5].
In some cases, the mechanisms remain unknown. Duringation of European Biochemical Societies.
Fig. 1. Categorization of alternative cell signal transduction pathways. See text for details [87–90]. (Abbreviations: CD40L, CD40 ligand; DR4/DR5,
death receptor 4/ death receptor 5; Fas, Fas antigen; FasL, Fas ligand; Gs, G proteins; HGF, hepatocyte growth factor; p21ras, Ras p21 protein; p42/
44, mitogen-activated protein kinase 1; p70S6K, ribosomal protein S6 kinase, 70 kDa; PKB, protein kinase B; SGK1, serum/glucocorticoid-regulated
kinase 1.)
Fig. 2. Divergent relationships between alternative pathways are illustrated as the logic gates. This illustration is purely conceptual, not in the sense
that the relationships are Boolean. Quantitative correlation is expected when the pathways are modeled at the kinetic level. See the text for details on
the examples. (Abbreviations: JAK2, Janus tyrosine kinase 2; LPS, lipopolysaccharide.)
5266 Y. Gong, Z. Zhang / FEBS Letters 579 (2005) 5265–5274diﬀerentiation of H19-7 neuronal cells by basic ﬁbroblast
growth factor, at least two signaling pathways are activated
by Ras (v-Ha-ras Harvey rat sarcoma viral oncogene homo-
log) and Src (v-src sarcoma viral oncogene homolog). Both
of them are required but not suﬃcient [6].
Synergistic eﬀects of alternative pathways were also observed
during host defense against pathogens, such as virus infection.
Infection of encephalomyocarditis virus induces accumulation
of dsRNA (double-stranded RNA), which elicit three pathways
leading to cytokine production and inﬂammatory and feb-
rile responses [7]. PKR (dsRNA-activated protein kinase)-
dependent and OAS (29–59 oligoadenylate synthetase)/
RnaseL-dependent pathways result in inhibition of translation,
which, synergistically collaborates with a novel alternative
pathway to result in MKK4 (MAPK kinase 4) and JNK
(c-Jun NH2-terminal kinase) activation (Fig. 3). The novel
alternative pathway also activates MKK3/6 and p38 MAPK(mitogen-activated protein kinase). Both activated JNK and
p38 MAPK induce expression of cytokines that are involved
in host defense (Fig. 3).
A further example of the synergistic eﬀects of the alternative
pathways is the Indian hedgehog (Ihh) cascade. Ihh is crucial
for the morphogenesis of the vertebrate skeleton. A subset of
Ihhs actions is fulﬁlled through parathyroid hormone-related
protein (PTHrP) pathway, such as prevention of chondrocyte
hypertrophy [8]. However, chondrocyte proliferation is depen-
dent on PTHrP-independent pathway(s) [9]. Thus, PTHrP-
dependent and -independent pathways are complementary
for skeleton morphogenesis.
2.2. Independent/redundant eﬀects of alternative pathways
The alternative pathways are redundant if one of them is
suﬃcient for the ﬁnal signaling. Thus it should be presented
as an OR gate (Fig. 2). The anti-apoptotic eﬀects of human
Fig. 3. Virus infection induced multiple signaling pathways in mam-
malian cell lines. This is an example of nested alternative pathways
(type N, see Fig. 1) during virus infection. Modiﬁed from [7].
(Abbreviation: 2-5A, 29–59-linked oligoadenylates.)
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are via the GM-CSF receptor and activation of Janus kinase
2 (JAK2). Two downstream alternative pathways are further
activated by JAK2, they are genistein-sensitive and PD98059-
sensitive pathways, respectively. Genistein or PD98059 alone
will not block the antiapoptotic eﬀects of GM-CSF, thus they
are redundant in the GM-CSF cascade [10].
2.3. Additive eﬀects of alternative pathways
The additive alternative pathways are similar to the redun-
dant pathways in that one of the alternative pathways is enough
to elicit the downstream signaling. However, the signal is ampli-
ﬁed when multiple pathways are eﬀective (Fig. 2). The additive
eﬀects can usually be found in the type V alternative pathways.
For example, during neuromuscular junction formation and
synaptogenesis, AchR (acetylcholine receptor) clustering in-
duced by laminin-1 and agrin are additive [11] (Fig. 2). Another
example is a type O alternative pathway, in which IGF-1R
(insulin-like growth factor 1 receptor) protects cells from apop-
tosis via three alternative pathways, PI3K (phosphoinositide 3-
OH kinase)-dependent, MAPK-dependent and mitochondrial
translocation of Raf (v-raf murine leukemia viral oncogene
homolog) pathways. The presence of multiple antiapoptotic
pathways explains the remarkable eﬃcacy of the IGF-1R in
protecting cells from apoptosis [12].
2.4. Opposite/adverse eﬀects of alternative pathways
It is interesting that the alternative pathways elicited by
one stimulus could have adverse eﬀects on the same target
(Fig. 2). Several examples have been identiﬁed experimentallyor inferred from experimental data. It was proposed that
RXR (retinoid X receptor)-driven rexinoid signalling through
two separate pathways, one would raises the TG (triglycerides)
in a PPARa-independent manner; a second one would
decrease TG through the PPARa-associated pathway [13]
(Fig. 2). Other cases of adverse eﬀects in type O alternative
pathways include the regulation of voltage-gated Ca2+ chan-
nels by b-adrenergic autoreceptors (b-ARs) [14], regulation
of sAPPa (nonamyloidogenic soluble form of the amyloid
precursor protein) secretion by h5-HT4 receptor [15] and
regulation of c-myc (v-myc avian myelocytomatosis viral
oncogene homolog) by interferon-c [16]. b-ARs aﬀect Ca2+
channels via two pathways, b1-AR-dependent and b2-AR-
dependent. The two alternative pathways have opposite eﬀects
on Ca2+ channel when responding to b-AR agonist isoprena-
line (ISO), with b1-ARs inducing slow potentiation and
b2-ARs inducing fast inhibition in rat chromaﬃn cells [14].
There are two alternative pathways linking h5-HT4 receptor
to sAPPa secretion. Increase in cAMP due to the activation
of AC (adenylyl cyclase) by Gs (G proteins) coupled to
h5-HT4 will increase sAPPa secretion, via a PKA independent
pathway. However, PKA, which is also activated by cAMP,
exerts a negative regulation on 5-HT induced increase in
secreted sAPPa [15]. IFN (interferen)-gamma elicits two path-
ways aﬀecting c-myc expression. Stat (signal transducer and
activator of transcription) 1-dependent pathway suppresses
the c-myc expression, whereas Stat1-independent pathway
activates the expression of c-myc [16].
2.5. Competitive alternative pathways
Competition of alternative pathways could be single-direc-
tional, in which one pathway and only one can suppress
another [17,18], or bi-directional, in which two pathways
mutually suppress each other [19] (Fig. 2). LPS (lipopolysac-
charide) activates both ERK (extracellular signal-regulated
kinase) 1/2 and NF-jB (nuclear factor kappa B) pathways.
The two pathways appear to contribute to TNF-a (tumor
necrosis factor-a) production competitively rather than addi-
tively. Basically, ERK may regulate NF-jB negatively, while
inhibition of NF-jB activation did not block LPS-activated
ERK1/2 MAPKs [17]. uPAR (urokinase plasminogen activator
receptor) activates ERK via both integrin, EGFR (epidermal
growth factor receptor)-dependent and alternative EGFR–
independent pathways. The alternative pathway functions only
in the absence of EGFR. When EGFR is expressed, it is
silenced [18]. Ras-transformed and metastatic NIH 3T3 ﬁbro-
blasts showed two diﬀerent protease-dependent invasive phe-
notypes, JNK-dependent and uPA (urokinase plasminogen
activator)-dependent rasuPA+/CL phenotype, and JNK-
independent and CL (cathepsin L)-dependent rasCL+/uPA phe-
notype. In CL-invasive phenotype JNK and c-Jun activities
were suppressed. In contrast, downregulation of c-Jun in cells
of phenotype rasuPA+/CL resulted in downregulation of uPA
mRNA levels and upregulated basal levels of CL mRNA. It
seems that the two alternative pathways compete to each other
by mutual suppression [19].3. Time course of the alternative pathways
One of the probable biological signiﬁcance of the alterna-
tive pathways could be the temporal regulation of the cell
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ways are expected, and already implied by several experimental
results. As described before, both laminin-1 and agrin activate
AchR clustering during neuromuscular junction formation
and synaptogenesis, and their eﬀects are additive [11]. How-
ever, they have diﬀerent time course, with the induction of
AchR clusters by laminin-1 occurring signiﬁcantly more slowly
than by neural agrin [11]. BlyS (B lymphocyte stimulator) is a
TNF family protein essential for peripheral B cell develop-
ment, functions primarily through attenuation of B cell apop-
tosis. In quiescent mature B cells, BlyS activates NF-jB
through both classical, p50/p65-dependent pathway and alter-
native, p52/RelB-dependent pathway, with distinct kinetics.
P50/p65 DNA binding activity is enhanced rapidly and tran-
siently, while p52/RelB is formed with delayed kinetics [20].
Multiple mechanisms are involved in induction of microtubule
damage and apoptosis by paclitaxel, including a JNK/SAPK
(stress-activated protein kinase)-dependent early phase and a
JNK/SAPK-independent late phase [21]. a-Thrombin induces
rapid Akt (v-akt murine thymoma viral oncogene homolog)
phosphorylation by b-arrestin1-dependent pathway, and indu-
ces sustained Akt phosphorylation by b-arrestin1-independent
pathway [22]. Cytosine arabinoside induces apoptosis in sym-
pathetic neurons via a rapid Bax (BCL2-associated X
protein)-dependent pathway and a delayed Bax-independent
pathway [23]. 4-HPR (fenretinide) had two distinct eﬀects on
murine embryonal carcinoma cells. One is rapid high concen-
tration eﬀect and receptor-independent, another is the delayed
low concentration eﬀect and receptor-dependent [24]. Immobi-
lized anti-CD3 (T-cell receptor) elicits both PKC-dependent
and PKC-independent alternative pathways for ERK activa-
tion. At the early phase, PKC-independent and DAG (diacyl-
glycerol)-dependent pathway is activated, while in the later
phase, PKC-dependent pathway is activated [25].4. Speciﬁcity of alternative pathways
The set of the alternative pathways represents the ability of
the cells to sense the alteration in their environments. However
they are not necessary functioning in all situations. Due to the
speciﬁcity of the gene expression and the existence of the vari-
ety of the signaling inter-mediators, the alternative pathways
could function in diﬀerent cells, organs, sexes and species.
These kinds of speciﬁcity could be part of the regulation mech-
anism for the cell functions.4.1. Cell-speciﬁc alternative pathways
ERK2 is activated via three potential pathways dependent on
the cell type and the stimulus. In RAT-1 or NIH 3T3 cell lines,
PDGF (platelet-derived growth factor) and insulin activate
ERK2 via p21ras, while EGF activates ERK2 via both p21ras
and Ca2+. In SWISS 3T3 cells, insulin activates ERK2 also
via p21ras, however PDGF and EGF activate ERK2 via both
p21ras and PKC pathways [26]. The cellular context, such as
lack of mediators or presence of inhibitors, will determine
which pathways would be used for ERK2 activation [26].
Cisplatin induces apoptosis in both cisplatin-sensitive human
ovarian cancer cell line A2780 and cisplatin-resistant subclones,
CP70 and C30. This is via caspase-3-independent pathway inA2780 cells, and via caspase-3-dependent pathway in CP70
and C30 cells [27].
4.2. Organ-speciﬁc alternative pathways
Eﬀects of rexinoid are through PPARa (peroxisome prolifer-
ator-activated receptor) in liver and kidney, but through an
alternative pathway in heart [13]. The expression of the Nkx-
6.1 homeodomain transcription factor is dependent on Shh
(Sonic hedgehog) signaling in the ventral neural tube and
spinal meninges, and Shh-independent in foregut [28]. Or-
gan-speciﬁc alternative pathways were also found in plant.
Members of pin2 (proteinase inhibitor II) gene family, pin2-
R and pin2-L, are speciﬁcally expressed in root and leaf,
respectively, responding to the same stimulus, jasmonic acid.
However, alternative pathways are utilized for the gene activa-
tion. The pathway involves protein phosphorylation in root,
and involves protein kinase in leaf [29].
4.3. Sex-speciﬁc alternative pathways
E2 (17b-estradiol) eﬀects on chondrocytes can be via nuclear
receptors, or alternatively, via a membrane receptor, which is
female-cell-speciﬁc. Downstream cell functions of the latter
pathway include alteration of the ﬂuidity of chondrocyte
membranes and PKC activation, which is dependent on G-
protein-coupled phospholipase C [30,31].
4.4. Species-speciﬁc alternative pathways
One example of species-speciﬁc alternative pathways was the
rexinoid eﬀects through PPARa, they are observed in rat pri-
mary hepatocyte cultures but not in cultures of rabbit or hu-
man origin [13].5. Sensitivity of alternative pathways
The alternative pathways could be elicited by diﬀerent kind
of stimulus or the same stimulus at diﬀerent strength or con-
centrations. This could be important for the ﬁne regulation
of the cell functions under similar circumstances but diﬀerent
in a few constituents or the quantity of the constituents.
5.1. Alternative pathways dependent on the strength of the
stimulus
4-Aminopyridine-evoked Ca2+-dependent release of gluta-
mate from hippocampal nerve terminals can be inhibited by
NO (nitrogen oxide). At low concentration of NO, the inhibi-
tory eﬀect is dependent on PKG (protein kinase G); however,
at high concentration of NO, PKG-independent mechanisms
could be involved in the inhibition [32]. Vasoactive intestinal
peptide (VIP) inhibits cytokine production in T lymphocytes.
Depending on VIP concentration, alternative pathways could
be elicited. At physical (low) concentration of VIP, it induces
less cAMP than FK, and the inhibition is via cAMP-indepen-
dent pathway. And at high concentration of VIP, the inhibi-
tion is via a cAMP-dependent pathway [33]. Tamoxifen and
4-hydroxytamoxifen at concentration of 10–20 lM elicit cell
apoptosis via estrogen receptor (ER)-independent pathway.
At submicromolar concentrations, they elicit cell apoptosis
via ER-dependent pathway [34]. In rice, a-amylase and inter-
node elongation induction by gibberellin is G-a-dependent
and with high sensitivity (eﬀective with low concentration of
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of G-a and with low sensitivity (elicited by high concentration
of gibberellin) [35].5.2. Alternative pathways dependent on the type of stimulus
The entrance of hair follicle into anagen involves migration
of keratinocyte, which could be induced by chemical or
mechanical stimulation. The spontaneous remodeling progres-
sion of anagen requires the Stat3-dependent pathway, while
artiﬁcially induced or physical perturbation of the follicles
induces an alternative Stat3-independent pathway for hair
regrowth. In both cases, PI3K activation is a prerequisite
[36]. Sometimes, the same molecule in diﬀerent states, such
as immobilized or in solution, could elicit alternative path-
ways. In T cell clone CTL, anti-CD3 could induce ERK acti-
vation via two alternative pathways, PKC-independent,
DAG-dependent pathway and/or PKC-dependent pathway,
depending on the stimulus. The immobilized anti-CD3 can
elicit both alternative pathways, while soluble cross-linked
anti-CD3 elicits only the PKC-dependent pathway [25].6. Alternative pathways during physiological and pathological
circumstances
Signal transduction pathways elicited during the onset of a
disease, due to the pathogen stimulation or arising of the
immuno-system, could be particularly interesting. Inhibition
of the pathogen-induced pathways, and/or the enhancement
of the defensive pathways could be leading to a therapy.
6.1. Alternative pathways in disease and defense against diseases
Cancer cells have some features, which are absent or under
strict control in normal cells, such as metastasis. The diﬀer-
ences could be traced at the molecule and signaling pathway
level. Furin is increased in cancers and responsible for the
invasion of tumor cells. Furin activates cell invasion via two
pathways, one is via MT1-MMP (membrane type matrix
metalloproteinase-1) activation, another is via TGFb matura-
tion. They converge at the point of MMP-2 activation, which
then promotes collagenolysis and invasion [37]. In prostate
cancer cells, IL-6 activates AR in an androgen-independent
manner. This activation itself involves two alternative path-
ways, STAT3-dependent and MAPK-dependent pathways
[38]. In diabetic patients, advanced glycation end products
(AGEs) mediates diabetic complications via both transforming
growth factor (TGF)-b-dependent and -independent path-
ways. In the TGF-b-independent pathway, Smad (SMA- and
MAD-related protein)2/3 activation is mediated by RAGE
(advanced glycosylation end product-speciﬁc receptor) and
ERK/p38 MAPKs. In the TGF-b-dependent pathways,
TGF-b is upregulated by AGEs and activates Smads via
TGF-b receptor [39].
Alternative pathways could be involved in the protective
mechanism upon infection. During lymphocytic choriomenin-
gitis virus infection, IFN-a/b cytokines are dominant in
promoting conditions for T cell IFN-c production. This
pathway is interleukin (IL)-12 independent. In the absence of
IFN-a/b functions, IL-12 can substitute to promote IFN-c
production. This alternative pathway is beneﬁcial but not suf-
ﬁcient for induction of optimal protection [40]. Necrosis usu-ally occurs under in-physiological circumstances. However, it
can also happen in vivo, and important for protective re-
sponse. Fas (TNF receptor superfamily, member 6) ligand in-
duces cell death via both caspase-8-dependent apoptosis and
caspase-8-independent but RIP (receptor-interacting protein)
kinase-dependent necrosis. Both apoptotic and necrotic T cells
can be captured by dendritic cells, but only necrotic cells acti-
vate dendritic cells to trigger lymphocyte activation. Thus dur-
ing T cell activation, a partial necrotic cell death may be
required for an eﬃcient ampliﬁcation of the immune response
[41].
6.2. Alternative pathways in physiology
Under physiological circumstances, multiple signaling path-
ways are usually recruited to fulﬁl speciﬁc functions. During
thrombus formation, signals from Thrombin, ADP (adenosine
diphosphate) and TxA2 (thromboxane A2) integrate at PLCb
(phospholipase C beta). Signals from PLCb and PLCc, which
is activated by Collagen, integrated at Ca2+ and DAG, both of
the latter converge at PKC or CalDAG-GEF I (calcium and
diacylglycerol-regulated guanine nucleotide exchange factor
I) [42]. During hematopoiesis, Notch often acts by inhibiting
diﬀerentiation along a particular pathway while permitting
or promoting self-renewal or diﬀerentiation along alternative
pathways [43].7. Robustness of cell physiology provided by the alternative
pathways
Robustness could be one of the most important features the
alternative pathways provide to the cell functions. The alterna-
tive pathways are thus backup for preparation of the dysfunc-
tion of one of the pathways. For example, two alternative
caspase-dependent pathways are responsible for death of
sympathetic neurons induced by NGF (nerve growth factor)
deprivation. They are caspase-2- and caspase-9-dependent
pathways, respectively. In wild-type neurons, caspase-2-depen-
dent pathway is the dominant, with caspase-9-dependent path-
way being suppressed by endogenous inhibitors of apoptosis
proteins (IAPs). In caspase-2-null neurons, elevated expression
of caspase-9 and DIABLO/Smac (direct IAP-binding protein
with low pI/second mitochondria-derived activator of caspase)
ensures the cell death and consequently the correct develop-
ment of the nervous system [44].8. Small molecule-induced alternative pathways
Elucidation of the eﬀects of natural or artiﬁcial chemical
compounds is important for drug screening. Usually the com-
pounds are expected to be antagonists or agonists of an in vivo
component, such as an enzyme or receptor. Experimental
results have shown that certain chemical compounds are able
to elicit alternative cell signaling pathways.
8.1. Drug induced alternative pathways
The heptapeptide TT-232 is a potential anticancer drug.
It triggers apoptosis, also induces cell cycle arrest through
PKCd and c-Src [45]. EGCG (major component of green tea)
inhibit vascular endothelial growth factor production via two
Table 1
Summarization of the behaviors/characteristics of alternative pathways
Behaviors/characteristics Possible biological importance
Relationships
Synergistic Signal integration
Independent Robustness
Additive Signal ampliﬁcation
Opposite/adverse Collaboration with other
pathways?Competitive
Time courses Temporal regulation
Speciﬁcity
Cell speciﬁc Spatial regulation
Organ speciﬁc ibid
Sex speciﬁc Evolution and gain of new
functionSpecies speciﬁc
Sensitivity
Stimulus strength dependence Fine tune of response
Stimulus type dependence Diﬀerential response
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3,12-dioxoolean-1,9-dien-28-oic acid), an antitumor drug,
activates a pathway for apoptosis in AML (acute myelogenous
leukemia) cells involving downregulation of FLIP (FLICE-like
inhibitory protein) and sensitization to TRAIL (tumor necrosis
factor-related apoptosis-inducing ligand). Most anticancer
drugs predominantly induce apoptosis through the intrinsic
(mitochondrial) pathway, CDDO and related compounds
may provide an alternative route to eradicating chemorefrac-
tory malignant cells [47].
8.2. Reverse regulation of alternative pathways by one compound
In some plants, respiration in mitochondria can be fulﬁlled
via two pathways, they are cytochrome pathway and alterna-
tive oxidase (AltOx) pathway. Treatment of the plant cells with
NO results in suppression of cytochrome pathway, but the
activation of AltOx pathway by upregulation of AltOx expres-
sion [48,49].Contexts
Physiological circumstance Development and homeostasis
Pathological circumstance Defense
Robustness related Resistance to genomic/
environmental alteration
Small molecule induced
Drug induced Evoluted response to
environments
Reverse regulation Collaboration with other
pathways?
Evolution Deﬁning new species9. Evolution of the alternative pathways
Ligation of Fas, TRAIL receptor-2 (TRAILR2) and TNF
receptor-1 (TNFR1) by their ligands all induces cell apoptosis
or necrosis, via alternative pathways. Apoptosis is mediated by
FADD (Fas-associated via death domain) and caspase-8, and
occurs during development and homeostasis. However, necro-
sis is mediated by RIP. During T cell necrosis, phosphorylation
of a key player of the death program by RIP kinase is necessary
[41]. Kinase-dependent cell death is also found in plants, sug-
gesting the evolutionarily highly conservation of kinase-
induced death [41,50]. A more signiﬁcant example of evolution
of alternative pathways can be found in the complement sys-
tems. In mammalian species, three pathways are involved in
the activation of this system, the lectin, alternative and classical
pathways (summarized in [51]). The complement components
of the alternative and lectin pathways have been identiﬁed in
echinoderms [52,53] and tunicates [54,55], both of them are
invertebrate deuterostomes. No matter how it was named,
the classical pathway appears in jawed ﬁsh for the ﬁrst time
[56,57]. A series of genome duplication events is thought to
result in the components of the classical pathway. Speciﬁcally,
C1q (complement component 1, q subcomponent), C1r/C1s,
C2, and C4, components of the classical pathway, were proba-
bly evolved from duplicates of ancestral mannose-binding
lectin, mannose-binding lectin-associated serine protease 1/2
(MASP1/2), factor B, and C3 molecules, respectively [57].10. Discussion
A signiﬁcant amount of the data on cell signal transduction
pathways, and the alternative pathways as well, has been doc-
umented, as exempliﬁed in previous sections and summarized
in Table 1. However we still have relatively little understanding
of the importance of the alternative pathways. In this section,
we discuss the potential biological impact of the alternative
pathways. Focuses are put on their relationships, time course
and speciﬁcation. The merit of elucidation of the alternative
pathways for cancer therapy will also be touched. Finally, bio-
chemical modeling as an essential tool for alternative pathway
research will be talked about.10.1. Why alternative pathways?
One of a few instances in which the alternative pathway
plays a relatively clear role is the T cell necrosis induced by
Fas ligand. Only necrotic cells, but not apoptotic T cells, acti-
vate dendritic cells to trigger lymphocyte activation that is
required for an eﬃcient ampliﬁcation of the immune response
[41]. For the synergic/additive alternative pathways, the impor-
tance could be residing in the information integration, as
illustrated recently for N-WASP (neural Wiskott–Aldrich syn-
drome protein) and Cdk2 (cyclin-dependent kinase 2) signaling
[3]. It was demonstrated that N-WASP is the place where
signals from Cdc42 and PIP2 (phosphatidylinositol 4,5-bis-
phosphate) are integrated, and Cdk2 is the place where signals
from Cyclin A and CDK-activating kinase are integrated [3].
The diﬀerential time courses and cell and organ speciﬁca-
tions of the alternative pathways, in general, imply their
involvement in the temporal–spatial regulation of cell func-
tions in a four-dimensional space and at the pathway level.
Understanding of spatiotemporal regulation of cell signaling
has been expected to be a new avenue for therapeutic interven-
tion [58]. Lipid rafts have been implicated to control spatial
and temporal regulation of signaling in cases such as Ras sig-
naling, actin cytoskeleton rearrangement and cell adhesion
[59,60]. However, further eﬀorts are still needed for elucidation
of the spatiotemporal control of alternative pathways, most
probably in the manner of case by case.
A widely accepted notion for the alternative pathways, espe-
cially the type O alternative pathways, is the provision of
mutational robustness. Two possible causes of mutational
Fig. 4. Activation of Raf/MEK/ERK and PI3K pathways by cytokine.
This is an example of the alternative pathways involved in tumori-
genesis. Modiﬁed from [72]. (Abbreviations: CREB, cAMP-responsive
element-binding protein; ETS, v-ets erythroblastosis virus E26 onco-
gene homolog; Grb2, growth-factor-receptor-bound protein2; GSK3,
glycogen synthase kinase 3; KSR, kinase suppressor of Ras; PDK1,
phosphoinositide-dependent kinase/PI3K-dependent kinase; PIP3,
phosphatidylinositol-3,4,5-trisphosphate; SOS, son of sevenless.)
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their relative importance [61]. They are distributed robustness,
due to the contribution of many diﬀerent parts of the system,
and gene redundancy, respectively. It was noticed that distrib-
uted robustness is a more poorly understood mechanism for
mutational robustness, and is equally or more important than
gene redundancy, which obviously provides a backup for the
mutation of an identical/similar gene [61]. Here we argue that
the two possible causes could be uniﬁed at the pathway level,
speciﬁcally, at the alternative pathway level. That is, no matter
how complex a system is, an alternative pathway(s) must be
used if a gene is mutated but a speciﬁc function, say the normal
growth of the cells, is still achieved. This can be exempliﬁed by
the NADPH (nicotinamide adenine dinucleotide phosphate,
reduced form) production, as cited in the reference [61].
NADPH, mostly produced by the pentose phosphate shunt
in wild cells, is made by transhydrogenase reaction using
NADH (nicotinamide adenine dinucleotide, reduced form)
from the tricarboxylic acid cycle in the E. coli cells carrying
loss-of-function zwf gene encoding the enzyme glucose 6-phos-
phate dehydrogenase, part of the pentose-phosphate shunt. It
would be even more straightforward to put the redundant gene
products into alternative pathways. Consequently, the prob-
lem of analysis of complex networks could be reduced to the
identiﬁcation and the analysis of the alternative pathways. In
this sense, alternative pathways could be seen not only as an
intrinsic designing of the bio-networks, but also a methodol-
ogy for their analysis. The situation is analogous to gene muta-
tion, that is not only a mechanism of genomic evolution, but
also a major tool for elucidating the gene function.
The opposite/adverse eﬀect of the alternative pathways
seems tricky. One further example in this category can be
found for TGF-b signaling, in which diﬀerent cell surface
receptors for TGF-b ligands are supposed to be responsible
for diﬀerential downstream events of TGF-b1 in endothelial
cells [62]. While ALK1 (activin receptor-like kinase 1) signals
repress expression of angiogenic factors and proteases via
Smad1/5 activation and play an important role during vascular
development, TbRI (transforming growth factor, beta receptor
I) elevates transcription of angiogenic factors and secretion of
proteases via Smad2/3 phosphorylation [63]. This signal diver-
sity and speciﬁcity is probably deﬁned by protein–protein
interaction [64], and the signal outcome in endothelia cells is
thus determined by the balance between the intermediate
receptors, ALK1 and TbRI [63]. A potential hypothesis for
the opposite eﬀects could be the cell regulation via cross-talk
between the alternative pathways in question and other path-
ways which inﬂuence the expression of the intermediates, such
as multiple cell surface receptors or cytosol adaptors.
Another tricky eﬀect between the alternative pathways is
competition. If the alternative pathways are type A, it will be
easier to explain the competition. Because the multiple path-
ways from the stimulus will aﬀect diﬀerent functions via diﬀer-
ent sets of the intermediates, which could be determined by
other pathways or other cell processes, a similar situation to
the opposite/adverse eﬀects. However, the examples listed
above are all type O alternative pathways [17–19]. It means
that even if the alternative pathways are elicited by the same
stimulus, and will reach the same target, they could compete.
In the example of ERK activation by uPAR via alternative
pathways [18], the authors explain the diﬀerential usage of
the alternative pathways as that, EGFR and an unknown pro-tein are involved in the pathways respectively, also they form a
complex with uPAR. However, the existence of EGFR in the
complex aﬀects the function of the unknown protein, thus
EGFR-dependent pathway is dominant [18]. While this expla-
nation could be right physically, completion of the physical
model is needed for hypothesizing its functional impact. The
dominance was recently proposed for Shc (Src homology 2
domain containing transforming protein)-dependent pathway
during MAPK activation by EGFR [65] (see below for details),
where the situation can also be formulated as a competition,
i.e., Shc-dependent pathways compete with Shc-independent
pathway. For explaining this result which seems not self-
contained, other pathways adopting Shc as a mediate had to
be involved [65].
10.2. What is meant to cancer therapy by alternative pathway
research?
At least some diseases, such as certain types of cancers,
involve activation or inhibition of multiple signaling pathways
[66]. Besides examples listed above, during cellular transforma-
tion induced by PDGF, both the Raf-MEK (mitogen-activated
protein kinase kinase)-ERK and PI3K pathways are activated
[67,68] (Fig. 4). Also, virtually all tumor-inducing DNA
viruses encode proteins inactivating both Rb (retinoblastoma)
and p53 [69–71]. The woven-up of the pathways may result in
unintended situations as we target a speciﬁc intracellular
component. There could be injurious eﬀects (invasive chemo-
therapeutic treatments) when the activity of a protein far
Fig. 5. A brief schema of the data structure of CellFrame. Shown are
major classes and their relationship.
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cell can bypass the inhibition via alternative pathways when a
downstream component (e.g., p90RSK [ribosomal protein S6
kinase, 90 kD] in Fig. 5) is inhibited [72]. This could partly
explain that cancer research is switching focus from on indivi-
dual genes to on pathway, although other reasons also hold,
such as there are many fewer pathways than genes [73]. This
also supports the emerging notion that multiple inhibitors
could be required for inhibition of transformation [74] or of
the transformed cells for eﬀective treatment [75,76].
10.3. Mathematically modeling as an important tool for
alternative pathway research
A powerful strategy for understanding the alternative path-
ways is the building and exploring of mathematical/kinetic
models. This involves two major steps. First is to elucidate
the circuits, second is to estimate the parameters for the steps
in the networks, such as the binding constants and the reaction
rates, and the initial concentrations of the network compo-
nents. Exploration of the established model using in silico
methodologies such as biochemical simulation will result in a
quantitative assessment of the relative contributions of the
alternative pathways, and the importance of the existence of
the alternative pathways could be hypothesized. The processes
could be iterative, and the hypothesis should be tested against
new data [77]. An example of model building and exploration
can be found for EGFR signaling cascade. The early modeling
for EGFR system focused on the EGF binding and the inter-
nalization of ligand-bound or -unbound EGFR [78,79]. The
induction of MAPK pathways as the major consequence of
the EGFR activation was recently modeled quantitatively as
a whole. The EGFR-MAPK model established by Brightman
and Fell in 2000 was aimed to interpret the quantitative diﬀer-
ences in EGF and NGF signalling in PC12 cells as the diﬀeren-
tial feedback regulation of the MAPK cascade. This was
achieved by constructing the basic model and then perturbing
the values of kinetic parameters governing a number of signal-
ing events [80]. A more recent EGFR-MAPK model was
published in 2002 [81]. This model focused on the comparisonof the signaling induced by cell surface and internalized
EGFRs, and deemed to be the most comprehensive by includ-
ing the fullest range of dynamic processes and making several
interesting, signiﬁcant and experimentally validated predic-
tions [79]. A major diﬀerence between the two EGFR-MAPK
models is that, both Shc-dependent and -independent path-
ways are included in the Schoeberl model but not in the Bright-
man model, which took into account Shc-dependent pathway
only. Inclusion of the alternative pathways makes the Schoe-
berl model possible to be used to assess the relative contribu-
tions of the distinct pathways to the ﬁnal signaling. This was
partly achieved by another recent work [65], in which the
Schoeberl model was explored with the biochemical simulator
Gepasi [82]. It was inferred that Shc-dependent pathway is
both redundant and dominant. For the Shc-dependent path-
way shares all other components with Shc-independent path-
way, it was ruled out that the existence of the alternative
pathways would contribute to the robustness. The hypothesis
is that Shc-dependent pathway is important for EGFR to com-
pete to other cell surface receptor cascades in which Shc is also
involved [65]. This could be the ﬁrst case of exploring an estab-
lished model for proposal of new hypothesis, and the hypoth-
esis could be testable with newly invented technologies such as
phospho-proteomics [83].
As discussed above, the opposite and competent eﬀects of
the alternative pathways are not self-contained and -inter-
preted, and other pathways and/or cell processes may have
to be involved. This implies that the local models, even if
mathematically built, could be insuﬃcient for our understand-
ing of the signaling networks, and large-scale models, probably
the whole cell models, are necessary to this end. Building of the
mathematical model in large-scale will involve integrating
bio-molecular interaction and cell perturbation data, both in
large-scale [77]. The interaction database BIND (biomolecular
interaction network database) is aimed speciﬁcally to docu-
ment interactions, complexes and pathways curated from the
literatures [84]. As the largest data source of the type, BIND
has included more than 190000 records from a variety of
species (http://bind.ca/). Similar large-scale database for cell
perturbation is still unavailable. On this regard, we are making
eﬀort to build a cell biology information system for the exper-
imental results on gene/protein expression and cell perturba-
tion, which is called CellFrame, and a prototype has been
proposed (http://cellframe.bioknowledge.org/; see Fig. 5 for
the brief schema). The databases, together with the algorithms
for reverse engineering and parameter estimation [85,86], are
expected to facilitate the establishment of large-scale bio-
networks and mathematical models, and to provide more
opportunities for assessing the importance of the alternative
pathways within the cell models.
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